DCRI and SAS Open Data to Researchers
A collaboration between The Duke Clinical Research Institute (DCRI) analytics, business intelligence and data management software and services provider SAS will give researchers access, analytics and data management tools to its database that includes 45 years of cardiovascular patient data collected by the Duke University Health System, including de-identified records for patients; data from more than 100,000 procedures; treatment histories, and more. The information can be used to test clinical hypotheses, develop clinical trial protocols and help researchers assess long-term outcomes and assess time trends. The DCRI and SAS are constructing a data governance plan to ensure the reliability of the data sets and to process requests as efficiently as possible. Researchers can apply for access to the data sets at soar.dcri.org. Read the full release here
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Obe-Cel Achieves High Response Rates, Durable Outcomes in r/r B-Cell Acute Lymphoblastic Leukemia
December 3rd 2024CAR T-cell therapy obecabtagene autoleucel produced high response rates, durable outcomes, and low toxicity in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, especially benefiting those with low-to-intermediate bone marrow burden.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Opdivo plus Yervoy Significantly Outperforms Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
December 2nd 2024Phase III CheckMate 8HW trial results demonstrated that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves progression-free survival and has a better safety profile compared to chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.
